Generic Copiktra Availability
Last updated on Sep 11, 2024.
Copiktra is a brand name of duvelisib, approved by the FDA in the following formulation(s):
COPIKTRA (duvelisib - capsule;oral)
Has a generic version of Copiktra been approved?
No. There is currently no therapeutically equivalent version of Copiktra available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copiktra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,312,718
Patent expiration dates:
- January 10, 2032✓
- January 10, 2032
-
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Patent 8,193,182
Issued: June 5, 2012
Inventor(s): Ren Pingda & Liu Yi & Wilson Troy Edward & Li Liansheng & Chan Katrina & Rommel Christian
Assignee(s): Intellikine, Inc.Chemical entities of Formula I:
Patent expiration dates:
- February 13, 2030✓
- February 13, 2030
-
Certain chemical entities, compositions and methods
Patent 9,216,982
Issued: December 22, 2015
Inventor(s): Ren Pingda & Liu Yi & Wilson Troy Edward & Li Liansheng & Chan Katrina & Rommel Christian
Assignee(s): Intellikine LLCChemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Patent expiration dates:
- January 5, 2029✓
- January 5, 2029✓
- January 5, 2029
-
Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Patent 9,840,505
Issued: December 12, 2017
Inventor(s): Ren Pingda & Martin Michael & Isbester Paul & Lane Benjamin S. & Kropp Jason
Assignee(s): Infinity Pharmaceuticals, Inc.Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Patent expiration dates:
- January 10, 2032✓
- January 10, 2032✓
- January 10, 2032
-
Processes for preparing isoquinolinones and solid forms of isoquinolinones
Patent RE46621
Issued: December 5, 2017
Inventor(s): Ren Pingda & Martin Michael & Isbester Paul & Lane Benjamin S. & Kropp Jason
Assignee(s): Infinity Pharmaceuticals, Inc.Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Patent expiration dates:
- May 17, 2032✓✓
- May 17, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 24, 2025 - TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
More about Copiktra (duvelisib)
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: PI3K inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
